STTK

NASDAQ 已收盘

Shattuck Labs

4.55 USD
▲+0.08+1.79%
盘后 4.64 +1.98%
2026-11-19
市值
$454.22M
市盈率
—
EPS
-0.51
股息率
—
52 周区间
1.88 – 8.33
成交量
1.39M
Beta
1.13
目标价
15.40
52W 低 1.8852W 高 8.33
价格走势

公司简介

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical...